MaxCyte (MXCT) Q4 2024 earnings summary

Executive summary

• Returned to core revenue growth in 2024, driven by strategic improvements, operational efficiency, and the acquisition and integration of SeQure Dx, expanding offerings in cell and gene therapy safety assessment.

• Expanded SPL (Strategic Partnership License) portfolio to 29 active customers, with 18 active clinical programs and one commercial program; signed a record six SPLs in 2024, including TG Therapeutics in early 2025.

• Supported the launch and global expansion of CASGEVY, the first approved non-viral cell therapy using the platform.

• Ended 2024 with $190.3 million in cash, cash equivalents, and investments, and no debt.

• Full year 2024 total revenue was $38.6 million, down 6% year-over-year; core revenue up 9% to $32.5 million.

Financial highlights

• Q4 2024 total revenue was $8.7 million, down 45% year-over-year due to prior year milestone payments; Q4 core revenue was $8.6 million, up 20% from Q4 2023.

• Instrument revenue for 2024 was $7.1 million, impacted by customer caution on capital expenditures; PA revenue grew 36% year-over-year.

• SPL program-related revenue was $6.1 million for 2024, ahead of guidance, with a small portion from CASGEVY royalties.

• Q4 2024 gross profit was $6.4 million (74% margin); non-GAAP adjusted gross margin was 84%.

• Ended 2024 with $190.3 million in cash, cash equivalents, and investments.

Outlook and guidance

• 2025 core revenue expected to grow 8%-15%, including at least $2 million from SeQure Dx.

• SPL program-related revenue for 2025 forecasted at approximately $5 million.

• Expected to end 2025 with about $160 million in cash and investments.

• Guidance assumes no significant change in the macroeconomic or funding environment.